Search Results (127)

The solid-state landscape of pharmaceutical compounds is often characterized by the occurrence of polymorphs, hydrates, and solvates, which may significantly influence their physicochemical and biopharmaceutical properties. In contrast, some active pharmaceutical ingredients exhibit a remarkable resistance to crystal form diversification, despite extensive experimental investigation. In the present work, vinpocetine was subjected to an extensive solid-form screening campaign aimed at exploring its propensity to generate alternative polymorphs, hydrates, and solvates. Mechanochemical experiments were performed under neat grinding and liquid-assisted grinding conditions using a broad range of organic solvents and water, including two-step milling procedures and formulations containing surfactants. Additional investigations included high-energy planetary milling, high-pressure compaction, exposure to controlled humidity, thermal cycling, slurry-bridging experiments in various media, and crystallization after mechanochemical neutralization of vinpocetine salts. The resulting solids were systematically characterized by powder X-ray diffraction, and thermal and morphological analyses. In all cases, the recovered solid corresponded to the commercially available crystalline form of vinpocetine, with no evidence of alternative polymorphs, solvates, or hydrates. These results demonstrate the unusual robustness of vinpocetine crystal structure across a wide range of mechanical, thermal, and solvent-mediated conditions. Notably, this behavior contrasts with the well-established ability of vinpocetine to form numerous salts and salt cocrystals, suggesting that solid-state diversification in this compound is primarily driven by proton-transfer processes rather than by neutral polymorphism or solvent incorporation. The present study provides experimentally defined boundaries for the solid-state landscape of vinpocetine and contributes valuable data for future crystal-form prediction and pharmaceutical development studies. Beyond the specific findings reported herein, the systematic documentation of both successful and unsuccessful experimental outcomes represents a valuable source of experimentally validated positive and negative data that may support the future development and validation of AI-assisted crystal-form prediction tools. Full article

Metal–organic frameworks (MOFs) are a versatile class of hybrid crystalline materials that have emerged as promising candidates for a broad range of applications. γ-cyclodextrin MOFs (γ-CD-MOFs) represent an innovative subgroup of MOFs constructed from “edible” γ-CD ligands coordinated with biocompatible metal ions to form an extended porous structure. Owing to their unique characteristics such as their “green” origin, biodegradability, and biocompatibility they became a promising platform for drug delivery applications. Structurally, γ-CD-MOF possess a body-centered cubic structure with dual-mode porosity, enabling the simultaneous encapsulation of hydrophilic and hydrophobic drugs. Such structural features contribute to high loading capacity, tunable release behavior, and enhanced stability of incorporated drugs. In this review, we comprehensively discuss the structural features of γ-CD-MOF, synthesis strategies, crystals size and morphology control, activation and drying techniques, and drug encapsulation approaches. We further address computational and simulation approaches used to predict and optimize drug-framework interactions, as well as post- synthetic modifications aimed at enhancing stability and functionality. The diverse pharmaceutical applications of γ-CD-MOFs are examined, including the delivery of small molecules, macromolecules, multi-drug systems, and emerging pulmonary formulations. Additionally, we examine biocompatibility and safety considerations and current limitations related to aqueous stability, industrial-scale production, and reproducibility. Finally, this review highlights recent progress and underlines future perspectives, emphasizing innovations such as fast drug-loaded MOF formation via spray-drying, co-delivery strategies, and vaccine-oriented formulations. Together, these insights highlight the potential of γ-CD-MOFs to shape the next generation of multifunctional drug delivery systems across interdisciplinary fields. Full article

This review summarizes innovative co-formulation strategies for non-marketed dry powder inhalers (DPIs), enabling the simultaneous pulmonary delivery of multiple active pharmaceutical ingredients (APIs). Key approaches include co-amorphous systems (COAMS) and co-crystals, which combine two APIs into a single particle, improving aerodynamic properties, solubility, dissolution, and patient compliance while reducing manufacturing complexity. Core–shell microparticles, produced via spray drying, allow spatial separation and controlled release of APIs, minimizing drug–drug interactions and enabling tailored pharmacokinetics. Co-spray drying of dual APIs can yield particles with superior aerosolization and stability, though examples remain limited. Nanoparticle-based systems offer enhanced lung deposition and cellular uptake but face challenges in device compatibility, scalability, and regulatory approval. Each technology presents unique advantages and limitations regarding manufacturability, dose flexibility, and clinical translation. This review also highlights advances in in vitro toxicity testing, including air–liquid interface cultures, organoids, lung-on-chip models, and precision-cut lung slices, which are increasingly important as alternatives to animal studies. The importance of using an aerosol exposure system for the testing is highlighted. Ultimately, the choice of co-formulation platform should balance scientific innovation with practical considerations of manufacturing and regulatory requirements to maximize therapeutic benefit and commercial viability for future DPI combination products. Full article

Background/Objectives: Cocrystallisation is a well-established path for altering the physicochemical properties and bioavailability of active pharmaceutical ingredients (APIs). A common side effect of anti-tubercular medicines is the depletion of group B vitamin reserves in TB patients. Co-administration of supplements such as pyridoxine (vitamin B₆) during TB therapy may be used to ameliorate the harmful side effects of vitamin B₆ deficiency. Methods: Mechanochemical grinding and solvent evaporation experiments using pyridoxine (PN) with 4-aminosalicylic acid (PAS) and separately with pyrazinecarboxylic acid (PCBA) were conducted. The bulk powder and crystal analysis was performed using FTIR, PXRD, DSC, TGA and SCXRD. Results: The isolation and characterization of two multicomponent salts containing pyridoxine, i.e., PN-PAS·H₂O and PN-PCBA, were completed. Mechanochemistry is an efficient method for the preparation of cocrystals. Conclusions: The drug–vitamin combinations may be useful for the development of new treatment regimens with potentially improved therapeutic outcomes and reduced adverse effects. Full article

The use of metal-based species bearing existing pharmaceuticals as ligands—often resulting in enhanced bioactivity—represents an attractive strategy for the development of novel therapeutic formulations. In this context, five well-known non-steroidal anti-inflammatory drugs (NSAIDs) were employed to substitute both PPh₃ and hydride ligands in [Ru(H)₂(CO)(PPh₃)₃] (1), thereby selectively affording neutral κ²-(O,O)–chelate complexes in satisfactory yields via molecular hydrogen release. Among the obtained species, two complexes coordinating diclofenac (4) and aspirin (5) were further investigated by single-crystal X-ray diffraction (SCXRD). Preliminary biological studies were conducted on the ruthenium–salicylic acid species 2 and ibuprofen 6. The former showed promising antiproliferative activity against HeLa cancer cells, consistent with the well-established role of NSAID–ruthenium(II) complexes as a platform for the development of novel anticancer metallotherapeutics. Full article

Pharmaceutical cocrystals are a well-established class of solid-state forms that can modulate the solubility, dissolution, stability, and bioavailability of active pharmaceutical ingredients without altering their molecular identity. Although traditional oral formulations have demonstrated translational potential, recent research has emphasized the importance of integrating cocrystals into emerging drug-delivery technologies. This review systematically analyzes recent advances in conventional and innovative cocrystal-based platforms, critically evaluating their therapeutic relevance. A comprehensive literature search was conducted, focusing on publications from the last decade, with emphasis on studies from 2020 to 2025, including peer-reviewed articles, patents, and regulatory documents. Evidence was organized into traditional oral, inhalable, intranasal, and transdermal formulations, followed by emerging platforms such as 3D printing, nano-cocrystals, and microneedles. Case studies and preclinical/clinical data were critically assessed to identify strengths, limitations, and future directions. Advancements in formulation science and novel delivery technologies are allowing pharmaceutical cocrystals to transition from laboratory innovations to clinical applications. Despite challenges in scalability, stability, and regulatory clarity, the application of cocrystals into emerging platforms highlights their potential as transformative tools in next-generation therapeutics. Full article

Coordination complexes play a crucial role in modern research. 4-benzopyranone-2-carboxylic acid is a fascinating class of molecules with numerous applications, including the synthesis of pharmaceuticals and valuable chiral compounds. Antibacterial and tuberculostatic medicines, HIV protease inhibitors, intermediates in organic synthesis, and organic catalysis are only a few of the biological applications of chiral complexes. In this study, the synthesis of four metal complexes, C₃₀H₂₈N₂NiO₁₂ [Ni(bzpyr)₂(py)₂(H₂O)₂] (I), C₃₀H₂₄CoN₂O₁₀ [Co(bzpyr)₂(py)₂(H₂O)₂] (II), C₂₀H₂₀O₁₃Zn [Zn(bzpyr)₂(H₂O)₃] (III), and C₃₀H₂₂CuN₂O₉ [Cu(bzpyr)₂(py)₂(H₂O)] (IV), is reported via direct reactions of 4-benzopyranone-2-carboxylic acid with metal salts and pyridine in anhydrous ethanol. Single-crystal X-ray diffraction analysis revealed that complexes I and II crystallize in the chiral space group P-1, whereas III and IV crystallize in the centrosymmetric space group P2₁/c. The structures of these complexes were further characterized by infrared spectroscopy, UV-Visible Diffuse Reflectance Spectroscopy, electrospray ionization mass spectrometry (ESI-MS), elemental analysis, nuclear magnetic resonance, electron paramagnetic resonance spectroscopy and single-crystal X-ray diffraction. In addition, the cytotoxic activities of complexes I–IV were evaluated against the human tumor cell lines K562, A549, HepG2, MDA-MB-231, and SW480, and molecular docking studies were conducted on the four complexes. Full article

Boronic acids are an important class of molecules diversely used in organic synthesis, catalysis, medicinal chemistry, and for the design of functional materials. Particularly, aryl boronic acids in the solid state are known to exhibit pharmaceutical and photoluminescent properties for antimicrobial, sensing, and drug delivery applications. Furthermore, the phenazine molecule is known for its diverse pharmacological properties, including antibiotic activity. In the case of molecular crystalline solids, it is well established that understanding noncovalent interactions remains key to designing or engineering their functional properties. While both aryl boronic acids and phenazine molecules individually represent an important class of compounds, their co-assembly in the crystalline state is of interest within the context of supramolecular chemistry and crystal engineering. Herein, we report the supramolecular features of two newly synthesized cocrystals, which are composed of para-F/CF₃-substituted phenylboronic acids, respectively, and phenazine, as demonstrated by structure analysis by single-crystal X-ray diffraction. Full article

Background/Objectives: Increasing the solid-state landscape of an active pharmaceutical ingredient (API) by generating new crystalline forms (e.g., polymorphs, cyclodextrin (CD) inclusion complexes, co-crystals, and salts) can yield products with significantly enhanced biopharmaceutical properties (especially increased water solubility), thereby improving API delivery and extending its lifetime. The aim of this study was the isolation of new solid forms of the poorly water-soluble non-steroidal anti-inflammatory drug fenbufen (FBF), for which relatively few solid phases have been reported to date. Further motivation for the study is the recent finding that it has potential for repurposing to treat acute pancreatitis. Methods: Interventions for generating new solid forms of FBF included (a) polymorph screening with a variety of solvent media, (b) attempts to form solid inclusion complexes with the native cyclodextrins α-, β-, and γ-CD using various preparative methods, and (c) co-crystallization with a series of coformers to produce co-crystals and/or molecular salts. Results: No new polymorphic forms of FBF were identified, but screening with CDs resulted in isolation and characterization of a new solid inclusion complex with γ-CD. However, co-crystallization of FBF with the water-soluble coformer isonicotinamide yielded two new products, namely a 1:1 co-crystal and an unusual multi-component ionic co-crystal, whose aqueous solubility indicated significant enhancement of FBF solubility. Conclusions: Due to its extremely low water solubility, FBF presented challenges during the study aimed at modifying its crystalline form. However, two new supramolecular forms, a co-crystal and an ionic co-crystal, were isolated, the latter phase having potential for further formulation owing to its significantly enhanced solubility. Full article

Addressing the limitations of poor piezoelectric photocatalytic activity and insufficient magnetic recovery in pure BiFeO₃ nanoparticles, Gd and Zr co-doped BiFeO₃ nanoparticles were synthesized via the sol-gel method. The structural characterization revealed a rhombohedral-to-orthorhombic phase transition with reduced grain size (~35 nm) and lattice distortion due to dopant incorporation. An XPS analysis confirmed Fe³⁺ dominance and oxygen vacancy enrichment, while optimized BGFZ9 exhibited enhanced remanent magnetization (0.1753 emu/g, 14.14 increase) compared to undoped BFO. The synergistic piezo-photocatalytic system achieved 81.08% Ofloxacin degradation within 120 min (rate constant: 0.0136 min⁻¹, 1.26 higher than BFO) through stress-induced piezoelectric fields that promoted electron transfer for ·O₂⁻/·OH radical generation via O₂ reduction. The Ofloxacin degradation efficiency decreased to 24.36% after four cycles, with structural integrity confirmed by XRD phase stability. This work demonstrates a triple-optimization mechanism (crystal phase engineering, defect modulation, and magnetic enhancement) for designing magnetically recoverable multiferroic catalysts in pharmaceutical wastewater treatment. Full article

This review systematically examines the pivotal applications of the Density Functional Theory (DFT) in drug formulation design, emphasizing its capability to elucidate molecular interaction mechanisms through quantum mechanical calculations. By solving the Kohn–Sham equations with precision up to 0.1 kcal/mol, DFT enables accurate electronic structure reconstruction, providing theoretical guidance for optimizing drug–excipient composite systems. In solid dosage forms, DFT clarifies the electronic driving forces governing active pharmaceutical ingredient (API)–excipient co-crystallization, predicting reactive sites and guiding stability-oriented co-crystal design. For nanodelivery systems, DFT optimizes carrier surface charge distribution through van der Waals interactions and π-π stacking energy calculations, thereby enhancing targeting efficiency. Furthermore, DFT combined with solvation models (e.g., COSMO) quantitatively evaluates polar environmental effects on drug release kinetics, delivering critical thermodynamic parameters (e.g., ΔG) for controlled-release formulation development. Notably, DFT-driven co-crystal thermodynamic analysis and pH-responsive release mechanism modeling substantially reduce experimental validation cycles. While DFT faces challenges in dynamic simulations of complex solvent environments, its integration with molecular mechanics and multiscale frameworks has achieved computational breakthroughs. This work offers interdisciplinary methodology support for accelerating data-driven formulation design. Full article

Paracetamol-4,4′-bipyridine cocrystals were synthesized using a solution method, reflux method, grinding method, and ultrasonic method. The structures and properties were characterized through the utilization of single-crystal X-ray diffraction (SXRD), powder X-ray diffraction (PXRD), polarized light microscopy (PLM), thermogravimetric analysis (TGA), elemental analysis (EA), and infrared spectroscopy (IR). The results show that the four methods synthesized different cocrystal morphologies, but the same structure and properties coupled with a notably high purity level. All featured strong hydrogen bonds formed between the paracetamol,4,4′-bipyridine and water molecules. An additional notable feature is the presence of π...π stacking interactions between the pyridine rings of adjacent 4,4′-bipyridine molecules. The solubility of paracetamol (active pharmaceutical ingredient, API) and the cocrystal was measured and discussed. In the dissolution experiment, the cocrystal showed a much faster dissolution rate than the API in simulated gastric fluid media (pH = 1.2). Furthermore, the pharmacokinetic (PK) behavior of the cocrystal and the API was investigated to evaluate the effectiveness of this strategy for enhancing the oral absorption of paracetamol. The in vitro and in vivo studies revealed that the paracetamol-4,4′-bipyridine cocrystal possessed an excellent dissolution behavior and an improved pharmacokinetic profile. Full article

Background/Objectives: This study investigates the preparation of coamorphous systems composed entirely of active pharmaceutical ingredients (APIs), namely praziquantel, niclosamide, and mebendazole. The objective was to formulate and characterize binary and ternary coamorphous systems to evaluate their structural, thermal, and stability properties. Methods: Ten different mixtures (binary and ternary) were designed through a mixture design approach and prepared using a sustainable, one-step neat grinding process in a lab-scale vibrational mill. The systems were prepared reproducibly within 4 h across the entire experimental domain. Structural characterization was performed using PXRD and FTIR to confirm the absence of crystalline domains and the presence of molecular interactions. The glass transition temperature (T_g) was theoretically calculated using the Gordon–Taylor equation for three-component systems and determined experimentally via DSC. Stability studies were conducted on seven systems under different storage conditions (−30 °C, 5 °C, 25 °C, and 40 °C) for six months. Results: PXRD analysis confirmed the formation of coamorphous systems with no crystalline phases. DSC revealed a single T_g for most systems, indicating homogeneity. Stability studies demonstrated that five out of seven systems adhered to the “T_g—50 °C” stability rule, remaining physically stable over six months. Recrystallization studies indicated diverse pathways: some systems reverted to their original crystalline phases, while others formed new entities such as cocrystals. Conclusions: This study highlights the feasibility of coamorphous systems composed of multiple APIs using a simple, solvent-free grinding approach. The findings underscore the importance of molecular interactions in determining stability and recrystallization behavior, offering insights for designing robust coamorphous formulations. Full article

Background/Objectives: The co-formulation of active pharmaceutical ingredients (APIs) is a growing strategy in biopharmaceutical development, particularly when it comes to improving solubility and bioavailability. This study explores a co-precipitation method to prepare co-formulated crystals of griseofulvin (GF) and dexamethasone (DXM), utilizing nanostructured, functionalized polylactic glycolic acid (nfPLGA) as a solubility enhancer. Methods: An antisolvent precipitation technique was employed to incorporate nfPLGA at a 3% concentration into the co-formulated GF and DXM, referred to as DXM-GF-nfPLGA. The dissolution performance of this formulation was compared to that of the pure drugs and the co-precipitated DXM-GF without nfPLGA. Results: Several characterization techniques, including electron microscopy (SEM), RAMAN, FTIR, TGA, and XRD, were used to analyze the nfPLGA incorporation and the co-precipitated co-formulations. The inclusion of nfPLGA significantly enhanced the dissolution and initial dissolution rate of both GF and DXM in the DXM-GF-nfPLGA formulation, achieving a maximum dissolution of 100%, which was not attained by the pure drugs or the DXM-GF formulation. The incorporation of nfPLGA also reduced the amount of time taken to reach 50% (T₅₀) and 80% (T₈₀) dissolution. T₅₀ values decreased from 52 and 82 min (for pure DXM and GF) to 23 min for DXM-GF-nfPLGA, and the T₈₀ improved to 50 min for DXM-GF-nfPLGA, significantly outpacing the pure compounds. Furthermore, incorporating nfPLGA into the crystal structures greatly accelerated the dissolution rates, with initial rates reaching 650.92 µg/min for DXM-GF-nfPLGA compared to 540.60 µg/min for DXM-GF, while pure GF and DXM showed lower rates. Conclusions: This work demonstrates that nfPLGA incorporation enhances dissolution performance by forming water channels within the API crystal via hydrogen-bonding interactions. This innovative nfPLGA incorporation method holds promise for developing hydrophobic co-formulations with faster solubility and dissolution rates. Full article

The solid form of the drug can directly affect the physicochemical properties, bioavailability, safety, and efficacy of the drug, and its types mainly include amorphous state, single-component polycrystalline, hydrate, solvate, salt, and cocrystal. Polymorphic drugs are solid drugs whose active ingredients exist in a specific crystalline state. Polymorphic drugs are solid drugs whose active ingredients exist in a specific crystalline state. Drug polymorphism refers to the presence of two or more different crystalline states of the drug. Pharmaceutical cocrystal is a new type of solid form that can improve the stability, solubility, and bioavailability of active pharmaceutical ingredients and many other physicochemical properties. The determination of the crystalline form of a drug and its content is of great significance in ensuring the quality of the polymorphic drug and its safety. In this paper, the quantitative analysis methods of polymorphs and pharmaceutical cocrystals are reviewed, the advantages and disadvantages of various methods are analyzed mainly from three types of techniques, namely, X-ray diffraction, spectroscopy, and thermal analysis, and the specific applications of various methods are commented on through examples. The analytical methods that can effectively determine the content of polymorphic drugs are comprehensively mastered to provide a reference for the establishment of quality standards for polymorphic drugs. Full article